drugset
Drugs / RPH-075
last change Mar 2026 re-read 3 minutes ago

RPH-075

also known as Keytruda
Developed for
cutaneous melanoma
Investigated by
Data Management 365 · Exacte Labs LLC · Federal State Budgetary Institution of the Central Research Institute of Epidemiology of Rospotrebnadzor · R-Pharm

Trials 1

today NCT06320353 · Ph 3
202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT06320353 Sep 2023 → Aug 2024 cutaneous melanoma R-Pharm Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as RPH-075 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06320353 ↗
Known as Keytruda “The goal of this double-blind, randomized study is to establish the equivalence of the efficacy, safety and immunogenicity of the drugs RPH-075 (international nonproprietary...” NCT06320353 ↗